Genmab

	8/5 15:57 af E L	doubt that it will impact Genmab at all for the coming years, but it is just 'sell first, ask later'...
	8/5 15:56 af E L	yeah... Trump said something again on MFN / internation drug pricing & medicaid... and healthcare the worst sector again... what a mess...
	8/5 15:43 af LP90	er det frygt for regnskabet der giver faldet eller er det USA der igen banker vores aktier ned Novo-Zealand osv.
	8/5 15:09 af Pensionisten	Ja, lidt trist p.t. - Novo, Genmab og Zealand gør godt nok det meget lidt kønne for porteføljen p.t. - Vi må nok væbne os med en stor portion af tålmodighed ;-)
	8/5 14:18 af YPE	Det er vel non-event?
	8/5 14:12 af gdn55	Meget lille tiltro til regnskabet, der kommer idag efter luk.
	8/5 14:09 af gdn55	i
	8/5 09:36 af E L	Lundbeck will present on the phase II AMULET trial, investigating amlenetug as a potential new treatment option targeting the rare neurological disorder, multiple system atrophy (MSA), -at the 2025 International MSA Congress in Boston, U.S., May 9-11. (link)
	7/5 20:15 af E L	Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom (link)
	7/5 17:59 af Raun	;-)
	7/5 14:00 af E L	can you also ask them to correct he mistake from kursmål 2000 DKK to kursmål 3000 DKK ? ;-) I think they had 3750 dkk at some point...
	7/5 13:32 af bikube	Handelsbanken har rettet fejlen i dag til kursmål 2000 DKK.
	7/5 08:53 af E L	small mistake in the currency
	7/5 08:51 af E L	Handelsbanken raises Genmab to buy (hold), target price SEK 2,000 (1,350) Published on 05/07/2025 (link)
	7/5 08:17 af gentogen	Se også 20:07 fra i aftes (EL)
	7/5 08:11 af Plimsoller	@LP90 Mon ikke det er Trumps melding om at der kommer en medicintold indenfor 14 dage?
	7/5 07:14 af Sukkeralf	NBI faldt 6% så massive børsbank til biotek generelt
	7/5 06:49 af LP90	Godmorgen :-) nogen forklaring på et fald i USA på 5,24% det dobbelte af det den faldt i DK ?
	6/5 20:54 af E L	World Ovarian Cancer Day & WOCCoalition @OvCancerDay · 3 u The World Ovarian Cancer Coalition is grateful to partners like @Genmab for its commitment to helping raise awareness of #ovariancancer globally and supporting all women at risk of, or diagnosed with, ovarian cancer, to help us reach our goal of #NoWomanLeftBehind. #WOCD2025 (link)
	6/5 20:33 af E L	Bispecific antibodies are generally regulated by CDER . CBER still regulates certain biologics like vaccines, blood products, and gene therapies, but for most bispecific antibodies used as therapeutics (such as those for cancer or autoimmune diseases), CDER is the responsible center
	6/5 20:23 af E L	To be clear : Although most biologics are regulated by the Center for Biologics Evaluation and Research (CBER), monoclonal antibodies, therapeutic proteins, and immunomodulators fall under CDER's regulatory oversight.
	6/5 20:07 af E L	awful day in pharma / bio on Vinay Prasad made Director of the Center for Biologics Evaluation and Research (CBER) at the US FDA. What a complete mess this administration... NBI , XBI , IBB all down 5 - 6 %
	6/5 19:35 af Raun	Så bløder vi igen :-(
	6/5 08:11 af E L	;-)

	6/5 07:43 af JKY_VH	Det indikerer et fortsat kurspotentiale på 58% iflg. Carnegie, så det går nok og god morgen:-)
	6/5 07:02 af ProInvestorNEWS	Genmab får lavere kursmål hos Carnegie (link)
	5/5 17:11 af Joakim Von And	Tak
	5/5 16:08 af gentogen	(link)
	5/5 14:41 af Joakim Von And	Hvornår er ASCO, det plejer at være ca. nu på året... Jeg har ikke fulgt så godt med.
	5/5 09:10 af lahn1	Købte lidt Bull næsten på bunden og tænker de for lov at sidde på bogen hen over regnskabet, mit kaffegrums siger stemminger vender med et godt regnskab og positiv FA overtager
	2/5 18:16 af Helge Larsen/PI-redaktør	Knock-Your-Socks-Off-News – May 2025 (link)
	2/5 15:24 af E L	As Amgen's trio of Horizon drugs disappoint, execs urge analysts to give them more time (link)
	2/5 13:54 af E L	In the European Union, we are preparing to launch following the recent positive opinion issued by the committee for medicinal products for human use on the approval of TEPEZZA for the treatment of moderate to severe thyroid eye disease in adults. This marks a significant step forward for patients living with TED who currently have no approved disease-modifying therapies available to them in Europe.
	2/5 13:54 af E L	Access has also improved for patients with more than 85% of medical plans, removing clinical activity score requirements. We are advancing our international expansion of TEPEZZA in Japan, TEPEZZA is now the first and only approved therapy for active thyroid eye disease. And in the first full quarter since launch, we've seen strong uptake and positive physician engagement.
	2/5 13:54 af E L	In the U.S., there are roughly 100,000 patients suffering from TED who could benefit from TEPEZZA and to reach them, we've intensified our efforts to engage a broad prescriber base of oculoplastic surgeons, ophthalmologists and endocrinologists. We are encouraged by the feedback that we are receiving from the medical community, including an increase in intent to prescribe reported by endocrinologists during the first quarter.
	2/5 13:54 af E L	Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript (link) I would note that within this portfolio, sales of TEPEZZA and KRYSTEXXA were adversely impacted in the quarter by changes to U.S. wholesaler inventory levels. We do not expect similar reductions in inventory levels for the remainder of the year. Since launch, TEPEZZA has had a positive impact for thousands of patients living with thyroid eye disease.
	2/5 11:56 af E L	;-)
	2/5 11:32 af lahn1	Thank you to ELNews :-)
	2/5 09:41 af E L	maybe easier to share the link also for the other AACR 25 posters for epcoritamab, tisotumab and Rina-s (link)
	2/5 09:35 af E L	AI radiomic biomarkers, using routine radiology scans, can potentially predict treatment response, assess early progression risk, and characterize response vs resistance mechanisms – improving the understanding of drug response to accelerate clinical development.
	2/5 09:34 af E L	We developed a custom AI radiomic biomarker for acasunlimab - Molecular profiling of NSCLC patients associates CT-based radiomic features with signaling pathways indicating a favorable tumor microenvironment for treatment with immunotherapy (link)
	2/5 09:27 af E L	AMGEN Q1 presentation (link)
	2/5 09:26 af E L	A Phase 3 study of TEPEZZA in Japan is enrolling patients with chronic/low clinical activity score thyroid eye disease (TED). A Phase 3 study evaluating the subcutaneous route of administration of teprotumumab is enrolling patients with TED.
	2/5 09:26 af E L	AMGEN QUARTER 1 2025 TEPEZZA® (teprotumumab-trbw) sales decreased 10% year-over-year to $381 million in the first quarter, primarily driven by 9% lower volume and 8% from a decrease in inventory levels, partially offset by higher net selling price. (link)
	2/5 09:07 af E L	Dr Lee likes talking about Rina-S... -Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer (link)
	2/5 07:09 af ProInvestorNEWS	Genmab håber på udvidet brug af kræftmiddel: Er på vej med ny ansøgning til myndighederne (link)
	2/5 06:10 af Helge Larsen/PI-redaktør	Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (link)
	1/5 20:00 af Darvin	Efter min mening er det absolut ikke timingen at udskifte Winkel. Ikke af forretningsmæssige grunde. Kan ikke få øje påfordelene. Men! Det kommer naturligvis indenfor en forholdsvis kort horisont - grundet alder og fornuft. Kender kan sagtens gå et par år, og sagtens flere.
	1/5 16:23 af E L	glad to see Pfizer still involved, as it is a small drug for them and they did pass on some responsibilities to Genmab. Hopefully it can lead to solutions to lessen the side effects on the eye
	1/5 16:20 af E L	New trial by Pfizer -A Study to Learn More About TIVDAK in Women With Cervical Cancer That Has Come Back - to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. (link)